Shengxiang Ren1, Qinrui Tian2, Nadav Amar3, Hui Yu3, Christopher J Rivard3, Charles Caldwell3, Terry L Ng3, Megan Tu4, Yiwei Liu2, Dexiang Gao5, Kim Ellison3, Kenichi Suda3, Leslie Rozeboom3, Gareth Rivalland6, Paul Mitchell6, Caicun Zhou2, Fred R Hirsch7. 1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 2. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. 3. Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 4. Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Surgery (Urology), University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 5. Departments of Statistics, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 6. Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Studley Rd, Heidelberg, VIC, Australia. 7. Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: fred.hirsch@ucdenver.edu.
Abstract
BACKGROUND: Herpes Virus Entry Mediator (HVEM) is an important immune checkpoint in cancer recognition. HVEM expressed on tumor cell membranes activates immune cell signaling pathways leading to either inhibition of activity (B- and T-lymphocyte attenuator, BTLA) or activation of immune activity (LIGHT). The aim of this study is to investigate the prevalence of HVEM expression and its association with PDL1 expression in NSCLC. METHODS: A TMA of 527 resected NSCLC samples and 56 NSCLC cell lines were evaluated for HVEM and PD-L1 expression. The IHC assay for HVEM was optimized on the Dako Link48 autostainer using a polyclonal antibody from R&D Systems(AF356). PD-L1 IHC was performed on the Dako Link48 autostainer using the PD-L1 28-8 pharmDx kit. Scoring HVEM employed the H-score system while for PD-L1 the tumor proportion score (TPS) was used. RESULTS: HVEM expression in the NSCLC resected samples and cell lines revealed a positive H-score more than 1 was 18.6% (77/415) and 48.2% (27/56) respectively. HVEM expression was significantly higher in patients with lymph node N2 metastasis (25.5% vs 7.9% vs 17.5%, p = 0.046) when comparing with N1 or no lymph node metastasis, and was marginally significantly higher in patients with stage III/IV disease (24.5% vs 16.4%, p = 0.059). Subgroup analysis showed that HVEM (median 45 vs 36 months, p = 0.706) and PD-L1 expression (median 45 vs 48 months, p = 0.178) status was not predictive of overall survival. HVEM was found to have a significant negative correlation with PD-L1 expression (r=-0.274, p < 0.001) in patients with NSCLC and also a weak negative correlation in NSCLC cell lines (r=-0.162, p = 0.352). CONCLUSION: HVEM was found to be overexpressed in NSCLC patients of N2 lymph node metastasis or later stage and has a negative co-relationship with PD-L1 expression. HVEM was not prognostic for NSCLC patients.
BACKGROUND:Herpes Virus Entry Mediator (HVEM) is an important immune checkpoint in cancer recognition. HVEM expressed on tumor cell membranes activates immune cell signaling pathways leading to either inhibition of activity (B- and T-lymphocyte attenuator, BTLA) or activation of immune activity (LIGHT). The aim of this study is to investigate the prevalence of HVEM expression and its association with PDL1 expression in NSCLC. METHODS: A TMA of 527 resected NSCLC samples and 56 NSCLC cell lines were evaluated for HVEM and PD-L1 expression. The IHC assay for HVEM was optimized on the Dako Link48 autostainer using a polyclonal antibody from R&D Systems(AF356). PD-L1 IHC was performed on the Dako Link48 autostainer using the PD-L1 28-8 pharmDx kit. Scoring HVEM employed the H-score system while for PD-L1 the tumor proportion score (TPS) was used. RESULTS:HVEM expression in the NSCLC resected samples and cell lines revealed a positive H-score more than 1 was 18.6% (77/415) and 48.2% (27/56) respectively. HVEM expression was significantly higher in patients with lymph node N2 metastasis (25.5% vs 7.9% vs 17.5%, p = 0.046) when comparing with N1 or no lymph node metastasis, and was marginally significantly higher in patients with stage III/IV disease (24.5% vs 16.4%, p = 0.059). Subgroup analysis showed that HVEM (median 45 vs 36 months, p = 0.706) and PD-L1 expression (median 45 vs 48 months, p = 0.178) status was not predictive of overall survival. HVEM was found to have a significant negative correlation with PD-L1 expression (r=-0.274, p < 0.001) in patients with NSCLC and also a weak negative correlation in NSCLC cell lines (r=-0.162, p = 0.352). CONCLUSION:HVEM was found to be overexpressed in NSCLCpatients of N2 lymph node metastasis or later stage and has a negative co-relationship with PD-L1 expression. HVEM was not prognostic for NSCLCpatients.
Authors: Michelle E Wakeley; Nicholas J Shubin; Sean F Monaghan; Chyna C Gray; Alfred Ayala; Daithi S Heffernan Journal: J Surg Res Date: 2019-09-12 Impact factor: 2.192
Authors: Nausicaa Malissen; Nicolas Macagno; Samuel Granjeaud; Clémence Granier; Vincent Moutardier; Caroline Gaudy-Marqueste; Nadia Habel; Marion Mandavit; Bernard Guillot; Christine Pasero; Eric Tartour; Robert Ballotti; Jean-Jacques Grob; Daniel Olive Journal: Oncoimmunology Date: 2019-09-25 Impact factor: 8.110